Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Bladder Cancer: KOL Insight [2017]

Product Code:
Publication Date:
August 2017

How will immune checkpoint inhibitors transform the treatment of Bladder Cancer?

Significant progress has been made over the past decade in bladder cancer as a host of new targeted therapies have emerged from the development pipeline. Five PD-1/PD-L1 immune checkpoint inhibitors have been approved but how are they set to impact treatment pathways? Which checkpoint inhibitor do the key opinion leaders (KOLs) think will dominate the market and how can each one successfully differentiate itself in a fast evolving landscape? Targeted agents such as Eli Lilly’s Cyramza are also in the pipeline but what are the most important factors to ensure utilisation of these novel agents?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on eight marketed products and four Phase III pipeline programmes

Request sample pages

Top Takeaways

  • What unmet needs exist in non-muscle invasive bladder cancer (NMIBC) and is the BCG vaccine addressing these needs? Will the conventional Bacillus Calmette–Guérin (BCG) vaccine retain its hold as standard of care in the high-risk NMIBC setting?
  • Which novel intravesical therapies are likely to treat NMIBC in the future and will they be embraced? Instiladrin (FKD Therapies/Merck & Co.), Vicinium (Eleven Biotherapeutics) and ALT-803 (Altor BioScience) are all in the Phase III pipeline but how are they perceived by KOLs?
  • Five PD-1/PD-L1 checkpoint inhibitors have been approved for advanced bladder cancer but which ones are KOLs most enthusiastic about? Find out how the immune checkpoint inhibitors are expected to impact bladder cancer and how these agents are perceived by regulatory authorities?
  • How do KOLs believe the immune checkpoint inhibitors can successfully differentiate themselves? How are KOLs weighing up each checkpoint inhibitor in terms of efficacy, safety, administration and access? Find out which checkpoint inhibitor has the most opportunity in the adjuvant setting or as a maintenance approach.
  • Can targeted agents such as Eli Lilly’s Cyramza forge a niche in the treatment algorithm? Based on results of the RANGE study, how do KOLs view Cyramza (ramucirumab) as a potential treatment for bladder cancer? What will be critical for commercial success in this indication?
  • Which innovative mechanisms of action are KOLs most excited about? Angiogenesis inhibitors and fibroblast growth factor (FGF) receptor inhibitors are all in the early-stage pipeline but are there any novel mechanisms that stand out to KOLs?
  • How will future treatment pathways evolve for the treatment of bladder cancer? Find out if immune checkpoint inhibitors or combination therapies are expected to play an important role.
Request sample pages

Back to the top


“A lot of patients will have a PD-1 inhibitor upfront. There may be a small group of patients with metastatic and more aggressive disease, who will be having [upfront] combinations of PD-1 and CTLA-4 inhibitors, or possibly IDO inhibitors.”
EU Key Opinion Leader

“It has been a hugely exciting time in the last two years. Suddenly, in bladder cancer, things are taking off. It's really quite exciting.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Valstar (valrubicin; Endo Pharmaceuticals)
  • TheraCys/Immucyst (BCG vaccine; Sanofi Pasteur/Merck & Co.)
  • Javlor (vinflunine ditartrate; Pierre Fabre)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS)
  • Imfinzi (durvalumab; AstraZeneca)
  • Bavencio (avelumab; Merck KGaA/Pfizer)

Pipeline Therapies

  • Cyramza (ramucirumab; Eli Lilly)
  • Instiladrin (SCH 721015; FKD Therapies/Merck & Co.)
  • Vicinium (VB4-845; Eleven Biotherapeutics)
  • ALT-803 (Altor BioScience)

KOLs Interviewed

KOLs from North America

  • Dr. Robert Dreicer, MD; Deputy Director of University of Virginia (UVA) Cancer Center, Director of Solid Tumor Oncology within the division of Hematology/Oncology and Professor of Medicine and Urology, at the University of Virginia School of Medicine, Virginia
  • Dr. Donald Lamm, MD, FACP; Clinical Professor at the University of Arizona and Director of the BCG Oncology practice in Phoenix, Arizona
  • Dr. Arlene O Siefker-Radtke, MD; Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, Texas
  • Dr. Daniel Petrylak, MD; Professor of Medicine (Medical Oncology) and of Urology at Yale Cancer Center and Co-Director of the Signal Transduction Research Program, Yale University, New Haven, Connecticut
  • Dr. David I. Quinn MBBS, PhD, FRACP FACP; Medical Director of the Norris Cancer Hospital and Clinics, Head of the Section of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of the University of Southern California (USC), California
  • Anonymous, US KOL; Professor of Medicine at a leading Oncology Institute

KOLs from Europe

  • Professor Robert Huddart MA (Oxon), MBBS, MRCP, FRCR, PhD; Leader of the Clinical Academic Radiotherapy team at the Institute of Cancer Research (ICR) in London, UK
  • Professor Dr. Theo M de Reijke, MD, PhD, FEBU; Professor of Urology at the Academic Medical Center (AMC), Amsterdam, Netherlands
  • Professor Robert Jones, MBChB, PhD; Professor of Clinical Cancer Research (Clinical Trials Research) and Consultant in Medical Oncology at the University of Glasgow, UK
  • Professor Morgan Roupret, MD, PhD; Academic Professor of Urology, Hopital Pitié-Salpétrière at the University of Paris, France
  • Professor Dr. Shahrokh F. Shariat, MD; Professor and Chairman of the Department of Urology at the Medical University of Vienna, Austria
  • Anonymous, German KOL; Professor of Urology at a leading German Institute

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved